pdufa.bio
Home › Decisions › SNY 2026-04-22

SNY FDA decision — Apr 22, 2026

✓ APPROVED

Sanofi — DUPIXENT (dupilumab) - (LIBERTY-CUPID) · Chronic Spontaneous Urticaria (CSU) in children ag.

Run-up into the decision (T-120 → T+5)

PDUFA 4/22/26$52.34$43.611/5/25
Daily close, T-120 (11/5/25) through T+5. Run-up high $52.34 on 11/21/25, low $43.6 on 3/16/26 (T-120 to T-1). FDA decision 4/22/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-04-22
OutcomeApproved
Drug / candidateDUPIXENT (dupilumab) - (LIBERTY-CUPID)
CompanySanofi
120-day run-up (T-120→T-1)-7.7%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio